Master the 2026 Chemo Immuno Admin Challenge – Ace the Test, Transform Lives!

Immunomodulators are specifically used for multiple myeloma due to their ability to enhance the immune response against cancer cells. These agents work by modifying the immune system's activity, which can lead to a reduction in the number of malignant cells and improvement in overall patient outcomes.

In the case of multiple myeloma, immunomodulators like thalidomide, lenalidomide, and pomalidomide are integral to treatment regimens. They not only have direct anti-cancer effects but also promote anti-tumor immunity by stimulating T-cells and natural killer (NK) cells, enhancing the body's ability to fight off the cancer.

In contrast, while breast cancer, colorectal cancer, and lung cancer may utilize a variety of treatment modalities, they do not rely specifically on immunomodulators as a primary treatment strategy in the same way that multiple myeloma does. Hence, the role of immunomodulators in these other types of cancer is not as pronounced or characteristic as it is in multiple myeloma.